FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | HPV

Older women unlikely to benefit from HPV vax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

A new study concludes that women over the age of 40 are unlikely to benefit from an HPV vaccine.

Researchers tracked the experiences of 9,000 Costa Rican women ages 19 to 97 years, screening them for HPV infections, which can trigger cervical cancer. The rate of newly detected infections plunge from 35 percent for women 19 to 25 to 13.5 percent for women over the age of 42. Typically those infections cleared up without treatment.

"Because the HPV vaccine can only prevent infections, and these women are not getting that many new infections, the potential benefit of HPV vaccination among older women is very limited," says Dr. Ana Cecilia Rodríguez, the lead author.

- check out the study abstract
- here's the report from the New York Times

Related Articles:
Study: HPV shot will slash cervical cancer rates
HPV vax successfully treats precancerous lesions

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Vaccine   HPV